期刊文献+

心房颤动抗栓治疗新进展

Advance of Antithrombotic Therapy in Atrial Fibrillation
下载PDF
导出
摘要 心房颤动患者具有很高的血栓栓塞的风险。近几年,心房颤动抗栓治疗特别是预防卒中治疗方面取得了很多进展,主要体现在抗凝治疗、抗血小板治疗、抗心律失常药物的应用及介入治疗等方面。本文将对心房颤动抗栓治疗进展进行回顾。 Patients with atrial fibrillation have high risk of thromboembolism. In recent years, many progresses have been made in the research of the antithrombotic therapy, especially the prevention of stroke in atrial fibrillation. It mainly reflected in the aspects of anticoagulation and antiplatelet therapy, the use of antiarrhythmic drugs, interventional therapy, etc. Advances of antithrombotic therapy in atrial fibrillation were reviewed in this paper.
作者 韩菲 杨中华
出处 《中国卒中杂志》 2010年第7期583-590,共8页 Chinese Journal of Stroke
关键词 心房颤动 卒中 抗栓 Atrial fibrillation Stroke Antithrombotic New advance
  • 相关文献

参考文献33

  • 1Connolly SJ. Preventing stoke in patients with atrial fibrillation:current treatments and newconcepts[J]. Am Heart J, 2003, 145:418-423.
  • 2Go AS, Hylek EM, Phillips JA, et al. Prevention of diagnosed atrial fribrillation in adults:national implications for rhythm management and stroke prevention[J]. JAMA, 2001, 285:2370-2375.
  • 3Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non- valvular atrial fibrillation:a systematic review and meta-analysis[J]. Thromb Res, 2006, 118:321-333.
  • 4FDA. FDA Approves Updated Warfarin (Coumadin) Prescribing Information[DB/OL]. [2007-10-08]. http:// www.fda.gov/bbs/top ics/NEWS/2007/NEW01684. html.
  • 5Miao L, Yang J, Huang C, et al. Contribution of age body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin:proposal for a new dosing regimen in Chinese patients[J]. Eur J Clin Pharm acol, 2007, 63:1135-1141.
  • 6Wadeliusm, Chen LY, ER Iksson N, et al. Association of warfarin dose with genes involved in its action and metabolism[J]. Hum Genet, 2007, 121:23-34.
  • 7The Internarional Warfarin Pharmacogenetics Consortium. Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data[J]. N Engl J Med 2009, 360:753-764.
  • 8Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest, 2008 133(6 suppl):160s-198s.
  • 9Diener HC. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation. Pooled analysis from the SPORTIF Ill and V studies. Department of Neurology, University of Essen, Hufelandstrasse 55, DE245122 Essen, Germany[J]. Cerebrovasc Dis, 2006, 21:279-293.
  • 10Petersen P, Grind M, ADLER J, et al. Ximelagatran verses warfarin for stroke prevention in patients with nonvalvular atrial fabrillationL SPORTIF II:a dose- guiding, tolerability and safety study[J]. J Am Cardiol, 2003, 41:1445-1451.

共引文献113

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部